SNY
SanofiMarquee-fund ownership over time
This quarter's activity
New positions opened
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Maverick Capital re-entered | Q3 2015 | 44Q | $33 | $43 | +27% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $49 | $43 | -12% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $49 | $43 | -12% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $49 | $43 | -12% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management 2× in & out | Q4 2025 | Q2 2026 | → $43 | -14% |
| Soros Fund Management | Q3 2024 | Q2 2025 | → $48 | -1% |
| Viking Global Investors | Q3 2024 | Q4 2024 | → $43 | -11% |
| Elliott Management | Q2 2015 | Q2 2020 | — | +0% |
| Berkshire Hathaway | Q3 2013 | Q4 2018 | → $32 | +6% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Sanofi. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Sep 14, 2021 — the most recent Form 4 on file — not from today.
- Form 40000899243-21-035757Sep 14, 2021
- Form 40000899243-21-031120Aug 2, 2021
- Form 40000899243-20-020587Jul 29, 2020
- Form 40001140361-20-013625Jun 11, 2020
- Form 40001140361-20-012718May 29, 2020
- Form 40001140361-20-005506Mar 11, 2020
- Form 40001140361-19-016600Sep 12, 2019
- Form 40000899243-19-020073Jul 23, 2019
- Form 40001140361-19-004808Mar 12, 2019
- Form 40000899243-19-003822Feb 15, 2019
- Form 40000899243-19-001575Jan 22, 2019
- Form 40001140361-18-038175Sep 10, 2018
- Form 40001140361-18-028055Jun 11, 2018
- Form 40000899243-18-014266May 29, 2018
- Form 40001140361-17-033562Aug 29, 2017
Fundamentals
XBRL · SanofiNot enough XBRL history to plot. Sanofihasn't tagged revenue, net income, EPS, or operating cash flow in the SEC us-gaap taxonomy with at least two fiscal-year periods — typical for SPACs / trust vehicles, pre-revenue biotechs, recent IPOs, and foreign filers reporting under IFRS.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Sanofi — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 6-KInterim disclosure (foreign)Jun 8, 2026
- 6-KInterim disclosure (foreign)May 27, 2026
- 6-KInterim disclosure (foreign)May 5, 2026
- 6-KInterim disclosure (foreign)Apr 29, 2026
- 6-KInterim disclosure (foreign)Apr 27, 2026
- 6-KInterim disclosure (foreign)Apr 23, 2026
- 6-KInterim disclosure (foreign)Apr 15, 2026
- 6-KInterim disclosure (foreign)Mar 31, 2026
- 6-KInterim disclosure (foreign)Mar 24, 2026
- 6-KInterim disclosure (foreign)Mar 10, 2026
- 6-KInterim disclosure (foreign)Mar 4, 2026
- 6-KInterim disclosure (foreign)Mar 3, 2026
- 6-KInterim disclosure (foreign)Feb 23, 2026
- 20-FAnnual report (foreign)Feb 17, 2026
- 6-KInterim disclosure (foreign)Feb 17, 2026
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Maverick Capital | Q2 2026 | open | $43 | $43 | -0% |
| Point72 Asset Management | Q4 2025 | Q2 2026 | $49 | $43 | -14% |
| Citadel Advisors | Q3 2024 | open | $49 | $44 | -10% |
| Soros Fund Management | Q3 2024 | Q2 2025 | $49 | $48 | -1% |
| Viking Global Investors | Q3 2024 | Q4 2024 | $49 | $43 | -11% |
| AQR Capital Management | Q3 2024 | open | $49 | $44 | -10% |
| Millennium Management | Q3 2024 | open | $49 | $44 | -10% |
| Point72 Asset Management | Q3 2024 | Q2 2025 | $49 | $48 | -1% |
| Maverick Capital | Q1 2023 | Q3 2023 | $40 | $46 | +16% |
| Maverick Capital | Q3 2016 | Q4 2016 | $27 | $27 | +4% |
| Maverick Capital | Q3 2015 | Q2 2016 | $33 | $26 | -21% |
| Elliott Management | Q2 2015 | Q2 2020 | $0.00 | — | +0% |
| Berkshire Hathaway | Q3 2013 | Q4 2018 | $31 | $32 | +6% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.